Senti Biosciences (SNTI) investor relations material

Executive summary

• Report covers the quarter ended June 30, 2026, for a clinical-stage biotech focused on gene circuit cell and gene therapies targeting incurable diseases.

• Company completed a holding company reorganization in April 2026 and entered a merger agreement in July 2026 to divest most of its business and pipeline.

• The merger will leave the company as a public entity with early-stage programs and contingent value rights (CVRs) for shareholders tied to SENTI-202 milestones.

Financial highlights

• Net loss was $12.8 million for Q2 2026, compared to $14.7 million in Q2 2025; net loss for the six months ended June 30, 2026, was $17.0 million, down from $28.8 million year-over-year.

• Revenue from collaborations was $17,000 for Q2 2026 and $33,000 for the six months, both related to a related-party option extension fee.

• Cash and cash equivalents were $6.5 million as of June 30, 2026, down from $16.4 million at year-end 2025.

• Accumulated deficit reached $375.5 million as of June 30, 2026.

• Operating expenses decreased year-over-year, mainly due to lower R&D and G&A costs and a $6.9 million one-time gain from a lease modification.

Outlook and guidance

• Management expects continued operating losses and negative cash flows as preclinical and clinical activities advance.

• Substantial doubt exists about the ability to continue as a going concern beyond Q4 2026 without additional funding.

• Additional capital will be required to maintain operations and pursue development strategy.